Orbis Allan Gray LTD Bristol Myers Squibb CO Transaction History

Orbis Allan Gray LTD

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 16, 2022	BUY	$61.48 - $73.72 $160,339 - $192,261	2,608 New	2,608 $190,000
Q2 2020 Aug 14, 2020	SELL	$54.82 - $64.09 $142,970 - $167,146	-2,608 Closed	0 $0
Q1 2020 May 15, 2020	SELL	$46.4 - $67.43 $254 Million - $369 Million	-5,479,261 Reduced 99.95%	2,608 $145,000
Q4 2019 Feb 14, 2020	BUY	$49.21 - $64.19 $270 Million - $352 Million	5,481,869 New	5,481,869 $352 Million
Q2 2019 Aug 14, 2019	SELL	$44.62 - $49.34 $29.3 Million - $32.4 Million	-656,994 Closed	0 $0
Q1 2019 May 15, 2019	SELL	$45.12 - $53.8 $156 Million - $186 Million	-3,458,095 Reduced 84.03%	656,994 $31.3 Million
Q4 2018 Feb 14, 2019	BUY	$48.76 - $63.23 $48.7 Million - $63.1 Million	998,296 Added 32.03%	4,115,089 $214 Million
Q3 2018 Nov 14, 2018	BUY	$55.19 - $62.25 $8.76 Million - $9.88 Million	158,735 Added 5.37%	3,116,793 $193 Million
Q2 2018 Aug 14, 2018	SELL	$50.53 - $62.98 $232 Million - $289 Million	-4,585,538 Reduced 60.79%	2,958,058 $164 Million
Q1 2018 May 15, 2018	BUY	$59.92 - $68.98 $38.5 Million - $44.3 Million	641,926 Added 9.3%	7,543,596 $477 Million
Q4 2017 Feb 14, 2018	BUY	$59.94 - $65.35 $98 Million - $107 Million	1,635,666 Added 31.06%	6,901,670 $423 Million
Q3 2017 Nov 14, 2017	BUY	$55.23 - $63.74 $291 Million - $336 Million	5,266,004	5,266,004 $336 Million

2,428

1.5B

29.7M

32.2M

Ticker BMY
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 2,126,160,000
Market Cap $113B
Description
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...

Get notified when there are updates to the investment portfolio of Orbis Allan Gray LTD, based on Form 13F filings with the SEC.

Stay updated on Orbis Allan Gray LTD with notifications on news.